CNS Clinical Trials: World Market Prospects 2011-2026

Date: December 22, 2010
Pages: 165
Price:
US$ 2,325.00
License [?]:
Publisher: Visiongain
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CADD67E33C6EN
Leaflet:

Download PDF Leaflet

CNS Clinical Trials: World Market Prospects 2011-2026
How will the CNS clinical trials sector develop from 2010, and where can you find the greatest opportunities there? Our new report shows you prospects for revenue growth worldwide, with contract research providers and sponsors of CNS clinical trials analysed.

Investment in R&D for central nervous system disorders comes second only to that of oncology. We show how you could make gains in the CNS sector, especially for treating neurological disorders. You can assess the potential of the industry and market now.

Our new study provides revenue forecasting with discussions of commercial drivers and restraints. It is your connection to the organisations, ideas and activities that are shaping the CNS trials sector. You can order our report now, staying ahead in your work.

What opportunities, challenges and requirements are there for companies developing CNS drugs? What role will CROs play in the expansion of the market? What revenue growth can the CNS clinical research sector achieve from 2010 to 2021?

Our report provides data on the current and future of the CNS clinical trials industry and market. We cover the overall world market and leading national markets, giving you the hard data and answers you need.

This decade, faster patient recruitment, improved assessments and important R&D developments will characterise industry leaders in CNS disorders. Companies will adapt to new trial designs and imaging technologies. Read our study to find out how.

We show you where the sector is heading from 2010 to 2021 - the events, technology and revenues. You can benefit by ordering now, staying ahead.

Analysis and expert opinion to aid your work - so you won't be left behind

Our new report provides you with revenue forecasts, market share analyses, R&D developments and expert opinion. We include 92 tables and figures and two expert interviews (shown in the accompanying lists).

You can stay ahead with our report, benefiting your analyses and commercial ideas:
  • Time-saving access to present and future industry trends, harnessing years of analytical knowledge
  • Data and discussions to benefit your market research, analyses and decision making
  • Tables, charts and lists to help make your reports, proposals, meetings, presentations and selling pitches more influential.

CNS Clinical Trials: World Market Prospects 2011-2026 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:
  • You will receive an overall forecast for the global CNS clinical trials market from 2010 to 2026
  • You will discover how costs/revenues will be split between in-house and outsourced clinical trials
  • You will investigate factors driving growth in the CNS clinical trials market, learning their effects on costs/revenues
  • You will find out which companies are key players in the market, those sponsoring trials and those CROs with most CNS expertise and experience
  • You will receive forecasts for the leading national markets from 2010 to 2026 (US and Canada, Germany, France, UK, Italy, Spain, Brazil, Russia, India and China)
  • You will identify key technological and policy developments likely to affect CNS clinical trials from 2010 onwards
  • You will discover the drivers, restraints, competition and opportunities influencing the CNS clinical trials sector, from the viewpoint of both trial sponsors and CROs
  • You will discover expert views from our survey, including full interview transcripts.
1. EXECUTIVE SUMMARY

1.1 Overview of Findings
1.2 Chapter Breakdown
1.3 Research Methods
1.4 Format of the Report
  1.4.1 Market Growth or Rising Costs?

2. CNS CLINICAL TRIALS: AN INTRODUCTION

2.1 Central Nervous System Disorders
  2.1.1 The Central Nervous System (CNS)
  2.1.2 Common CNS Disorders
  2.1.3 Causes of CNS Disorders
  2.1.4 The CNS Drug Market 2009
2.2 Clinical Trials
  2.2.1 A Brief History of Clinical Trials
    2.2.1.1 The Nuremburg Code and the Declaration of Helsinki
    2.2.1.2 Council for International Organizations of Medical Sciences (CIOMS)
    2.2.1.3 Good Clinical Practice
2.3 Phases of Clinical Trials
  2.3.1 Phase I Trials
  2.3.2 Phase II Trials
  2.3.3 Phase III Trials
  2.3.4 Phase IV Trials: Post-Marketing Surveillance
2.4 Clinical Research Outsourcing

3. GLOBAL CNS CLINICAL TRIALS MARKET 2010-2026

3.1 The Global CNS Clinical Trials Market in 2010
  3.1.1 CNS Clinical Trials in 2010, by Phase
  3.1.2 Value of the CNS Clinical Trials Market in 2010
3.2 Leading Sponsors of CNS Clinical Trials in 2010
  3.2.1 GSK
  3.2.2 Pfizer
  3.2.3 Novartis
  3.2.4 AstraZeneca
  3.2.5 J&J
3.3 CNS Clinical Trials: Market Forecast 2011-2026
  3.3.1 Significant Unmet Needs to Drive Growth
  3.3.2 Increasing Emphasis on Late-Stage Trials
  3.3.3 CNS Clinical Trials Market: 2011-2016
  3.3.4 CNS Clinical Trials Market: 2016-2021
  3.3.5 CNS Clinical Trials Market: 2021-2026
3.4 In-house vs. CROs
  3.4.1 Clinical Research Outsourcing
  3.4.2 CNS CRO Market to Grow from 2011

4. LEADING NATIONAL MARKET FORECASTS 2011-2026

4.1 Regional CNS Clinical Trials Markets 2010
4.2 Regional CNS Clinical Trials Markets: Forecast 2011-2026
4.3 US and Canada
4.4 Europe
  4.4.1 Europe: Half Emerging, Half Established
  4.4.2 Western Europe
    4.4.2.1 Market Forecast 2011-2026
4.5 BRIC Nations
4.6 Brazil
  4.6.1 CNS Clinical Trials in Latin America
4.7 Russia
4.8 India
4.9 China
  4.9.1 Chinese Interest in CNS Disorders Set to Increase
4.10 Other Emerging Markets
  4.10.1 CEE
  4.10.2 South East Asia

5. LEADING COMPANIES PROVIDING CRO SERVICES FOR CNS CLINICAL TRIALS

5.1 Quintiles
  5.1.1 Expertise in CNS Clinical Trials
  5.1.2 Recent Developments and Growth Strategies
5.2 Covance
  5.2.1 Financial Performance 2009
  5.2.2 Covance CNS Experience
  5.2.3 Industry Partnerships
5.3 Pharmaceutical Product Development (PPD)
  5.3.1 Financial Performance 2009
  5.3.2 CNS: Over 330 Trials in Five Years
  5.3.3 Expanding in Eastern Europe
  5.3.4 Vaccines and Biologics
5.4 Charles River Laboratories
  5.4.1 Financial Performance 2009
  5.4.2 Interest in CNS Development
5.5 Parexel
  5.5.1 Financial Performance 2009
  5.5.2 Experts in CNS Clinical Trials
5.6 ICON
  5.6.1 Financial Performance 2009
  5.6.2 Ten Years of CNS Experience
  5.6.3 Expanding into Biomarkers and Imaging
5.7 Kendle
  5.7.1 Financial Performance 2009
  5.7.2 CNS Clinical Trial Capabilities
5.8 PRA International
  5.8.1 CNS Clinical Trial Experience
5.9 PharmaNet Development Group
  5.9.1 PharmaNet Neuroscience
  5.9.2 Emerging Market Expansion
5.10 CNS Specialists
5.11 CROs Specialising in Pre-clinical CNS Services
  5.11.1 Biotrofix
  5.11.2 CNS-CRO
5.12 CNS Patient Recruitment Services
  5.12.1 QCTR
  5.12.2 Alliance Research Group
5.13 Early-stage CNS CROs
  5.13.1 CNS Network
  5.13.2 Forenap
  5.13.3 Lifetree Clinical Research
5.14 Some Companies Specialise in All Development Phases
  5.14.1 Tangent Data
  5.14.2 Comprehensive NeuroScience (CNS)
5.15 Imaging and Testing for CNS Trials
  5.15.1 Neuroimage
  5.15.2 Miicro
  5.15.3 Cogtest

6. INDUSTRY TRENDS FROM 2011

6.1 SWOT Chart for CNS Trial Sponsors: 2010-2026
  6.1.1 High Cost, Low Success
  6.1.2 Money-Saving Opportunities
  6.1.3 High Placebo Response Rates
6.2 SWOT Chart for CROs in the CNS Sector: 2010-2026
  6.2.1 More-efficient Trials
  6.2.2 Big Pharma M&A to Boost CRO Growth
    6.2.2.1 Strategic Partnering
  6.2.3 Patient Recruitment and Enrolment
6.3 Suicidality
  6.3.1 The Columbia Suicide Severity Rating Scale (C-SSRS)
  6.3.2 Man vs. Machine
6.4 Alternative Trial Design
  6.4.1 Delayed-Start Trials
  6.4.2 Challenges with Delayed-start Trials
  6.4.3 Case Study: The ADAGIO Trial
  6.4.4 Adaptive Clinical Trials
6.5 Neuroimaging
  6.5.1 Neuroimaging Biomarkers
  6.5.2 Neuroimaging and Future Drug Development
  6.5.3 Alzheimer's Disease
  6.5.4 Alzheimer's Disease Neuroimaging Initiative
6.6 CNS Target Compounds Are Changing
  6.6.1 Neuroprotective Drugs
  6.6.2 Biologics & Biosimilars
6.7 Benefits and Challenges to Outsourcing CNS Trials
  6.7.1 Large Patient Populations
  6.7.2 Genetic Variations
6.8 Challenges Faced by Large Pharma Companies in CNS R&D
6.9 Animal Models Must Be Improved Upon

7. EXPERT OPINION

7.1 Professor Alan Palmer, Chief Scientific Officer and Co-founder, MS Therapeutics
  7.1.1 Neuroimaging and CNS Drug Development
  7.1.2 Delayed-start Trials for CNS Diseases
  7.1.3 Patient Recruitment in CNS Clinical Trials
  7.1.4 Changing Priorities in CNS Drug Development
  7.1.5 Therapeutic Areas That Will See Increased Investment
  7.1.6 Threats to CNS Drug Development and Clinical Trials
7.2 Dr Amir Kalali, Vice President, Medical and Scientific Services and Global Therapeutic Group Leader, CNS at Quintiles
  7.2.1 Challenges in Neuroimaging Biomarkers
  7.2.2 Placebo Problems in CNS Clinical Trials
  7.2.3 CROs in the CNS Clinical Trials Market
  7.2.4 Failure Rate in CNS R&D
  7.2.5 Big Pharma and CNS R&D
  7.2.6 Globalisation
  7.2.7 Challenges in CNS Clinical Trials

8. CONCLUSIONS

8.1 There Will Be Growth Throughout the Period
  8.1.1 Unmet Needs to Drive Growth
8.2 CROs Will Play a Larger Role in the Market
8.3 Increasing Use of Neuroimaging
8.4 Emerging Markets to Drive Growth
  8.4.1 India and China

LIST OF TABLES

Table 2.1 World CNS Disease Drug Market, 2009
Table 2.2 Members of the ICH, 2010
Table 3.1 CNS Clinical Trials by Phase, 2010
Table 3.2 CNS Clinical Trials Market, 2010
Table 3.3 Top 25 Big Pharma Sponsors of CNS Clinical Trials, 2010
Table 3.4 GSK's Neuroscience Pipeline, February 2010
Table 3.5 Pfizer's Neuroscience Pipeline, September 2010
Table 3.6 Novartis CNS Clinical Trials Enrolling in November 2010
Table 3.7 AstraZeneca's Neuroscience Pipeline, 2010
Table 3.8 Janssen-Sponsored Clinical Trials, 2010
Table 3.9 World CNS Clinical Trials Market Forecast, 2010-2018
Table 3.10 World CNS Clinical Trials Market Forecast, 2018-2026
Table 3.11 CNS Clinical Trials Drivers and Restraints, 2011-2026
Table 3.12 CRO and In-house Market Shares, 2010-2026
Table 3.13 CNS CRO Market Drivers and Restraints, 2011-2026
Table 4.1 CNS Clinical Trials Market by Region, 2010
Table 4.2 CNS Clinical Trials Market: National Forecasts, 2010-2018
Table 4.3 CNS Clinical Trials Market: National Forecasts, 2018-2026
Table 4.4 CNS Clinical Trials Market Regional Shares, 2010-2026
Table 4.5 CNS Clinical Trials Registered in US and Canada by Phase, 2010
Table 4.6 US and Canadian Market Drivers and Restraints, 2011-2026
Table 4.7 European CNS Clinical Trials by Phase, 2010
Table 4.8 EU Membership Status of CEE Countries, 2010
Table 4.9 CNS Clinical Trials in Selected Western European Countries by Phase, 2010
Table 4.10 Western Europe Market Drivers and Restraints, 2011-2026
Table 4.11 Relative Cost of Conducting Clinical Trials in Western Europe, 2010
Table 4.12 CNS Clinical Trials in BRIC Nations, 2010
Table 4.13 Latin American Market Benefits and Challenges, 2011-2026
Table 4.14 Russian Market Drivers and Restraints, 2011-2026
Table 4.15 Indian Market Benefits and Challenges, 2011-2026
Table 4.16 Chinese Market Benefits and Challenges, 2011-2026
Table 4.17 CNS Disorder Prevalence in South East Asia, 2010
Table 5.1 Number of CNS Clinical Trials Performed by Company, 1990-2010
Table 5.2 CROs Offering CNS Services Not Discussed in This Report, 2010
Table 5.3 Covance Sales by Market Segment, 2009
Table 5.4 PPD Sales by Market Segment, 2009
Table 5.5 Parexel Sales by Market Segment, 2009
Table 5.6 ICON Sales by Region, 2009
Table 5.7 Kendle Sales by Market Segment, 2009
Table 5.8 Kendle Sales by Region, 2009
Table 5.9 CNS Specialist CROs Not Discussed in This Report, 2010
Table 6.1 SWOT Chart for CNS Clinical Trial Sponsors, 2011-2026
Table 6.2 SWOT Chart for CROs Conducting CNS Clinical Trials, 2011-2026
Table 6.3 C-CASA Levels of Suicidality, 2010
Table 6.4 Some Companies Offering Neuroimaging Services for CNS Clinical Trials, 2010
Table 6.5 Levels of Biomarker, 2010
Table 6.6 Selected Treatments Targeting Amyloid-?, 2010
Table 8.1 CNS Clinical Trials Market Forecast, 2010-2026
Table 8.2 CNS Clinical Trials Market by Region, 2010-2026

LIST OF FIGURES

Figure 2.1 World CNS Diseases Drug Market, 2009
Figure 2.2 The Drug Development Process, 2010
Figure 3.1 CNS Clinical Trials by Phase, 2010
Figure 3.2 CNS Clinical Trials Market, 2010
Figure 3.3 Top 25 Big Pharma Sponsors of CNS Clinical Trials, 2010
Figure 3.4 GSK's Neuroscience Pipeline, February 2010
Figure 3.5 Pfizer's Neuroscience Pipeline, September 2010
Figure 3.6 AstraZeneca's Neuroscience Pipeline, 2010
Figure 3.7 World CNS Clinical Trials Market, 2010-2026
Figure 3.8 World CNS Clinical Trials Market, 2016
Figure 3.9 World CNS Clinical Trials Market, 2021
Figure 3.10 World CNS Clinical Trials Market, 2026
Figure 4.1 CNS Clinical Trials Market by Region, 2010
Figure 4.2 CNS Clinical Trials Market by Region, 2016
Figure 4.3 CNS Clinical Trials Market by Region, 2021
Figure 4.4 CNS Clinical Trials Market by Region, 2026
Figure 4.5 US and Canada CNS Trials Split by Country, 2010
Figure 4.6 US and Canada CNS Trials by Phase, 2010
Figure 4.7 US and Canada: CNS Clinical Trials Market, 2010-2026
Figure 4.8 European CNS Trials by Phase, 2010
Figure 4.9 CNS Clinical Trials in Selected Western European Countries, 2010
Figure 4.10 CNS Clinical Trials in Selected Western European Countries by Phase, 2010
Figure 4.11 Selected Western European Countries: CNS Clinical Trials Market, 2010-2026
Figure 4.12 CNS Clinical Trials in BRIC Countries, 2010
Figure 4.13 CNS Clinical Trials in BRIC Countries by Phase, 2010
Figure 4.14 BRIC National CNS Clinical Trials Markets, 2010-2026
Figure 4.15 CNS Clinical Trials in Brazil by Phase, 2010
Figure 4.16 CNS Clinical Trials in Russia by Phase, 2010
Figure 4.17 CNS Clinical Trials in India by Phase, 2010
Figure 4.18 CNS Clinical Trials in China by Phase, 2010
Figure 4.19 Other CNS Clinical Trials Markets, 2010-2026
Figure 4.20 CNS Disorder Prevalence in South East Asia, 2010
Figure 5.1 Number of CNS Clinical Trials Performed by Company, 1990-2010
Figure 5.2 Covance Sales by Market Segment, 2009
Figure 5.3 Covance Sales by Region, 2009
Figure 5.4 PPD Sales by Market Segment, 2009
Figure 5.5 Charles River Laboratories Sales by Market Segment, 2009
Figure 5.6 Parexel Sales by Market Segment, 2009
Figure 5.7 ICON Sales by Region, 2009
Figure 5.8 Kendle Sales by Market Segment, 2009
Figure 5.9 Kendle Sales by Region, 2009
Figure 6.1 Suicidality and the FDA, 2003-2008
Figure 6.2 The Delayed-start Trial DesignŠ°

COMPANIES LISTED

Abbott
AbC.R.O.
Alcon Laboratories
Allergan
Alliance Research Group
Allphase Clinical Research
Apollo Hospitals Group
Aptuit
Association of Clinical Research Organizations (ACRO) [US]
Astellas Pharma
AstraZeneca
Averion International
Baxter Healthcare
Bayer
Behavioral & Medical Research
BioClinica
Biogen Idec
BioScape
Biotrofix
Boehringer Ingelheim
Bristol-Myers Squibb
Caprion Proteomics
Cerebricon
Charles River Laboratories
Chiltern International
Clinica Research Foundation EEU
ClinInvent Research
CMIC Co
CNS Clinical Trials (Comprehensive NeuroScience subsidiary)
CNS Healthcare
CNS Network
CNS Response
CNS Vital Signs
CNS-CRO
Cogtest (subsidiary of The Cognition Group)
Columbia University (US)
Comprehensive NeuroScience
Council for International Organizations of Medical Sciences (CIOMS)
Covance
Dr. Reddy's Laboratories
Eisai
Ekam Imaging
Elan
Eli Lilly
Encorium
eResearch Technology (ERT)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
Forenap Pharma
Forest Laboratories
Friedrich Miescher Institute for Biomedical Research (Switzerland)
GE Healthcare
Genstar Capital
Genzyme
Global CNS Research
GlaxoSmithKline (GSK)
Guy's and St Thomas' NHS Foundation Trust (UK)
i3 Research
ICON
INC Research
Institute of Medicine (US)
International Conference on Harmonisation (ICH)
Janssen Alzheimer Immunotherapy
Janssen Korea
Janssen Pharmaceutica (Belgium)
Janssen Pharmaceutical (Japan)
Janssen-Cilag
Janssen-Ortho
Japan Pharmaceutical Manufacturers Association (JPMA)
JLL Partners
Johnson & Johnson Pharmaceutical Research and Development
Johnson & Johnson (J&J)
Jubilant Biosys (subsidiary of Jubilant Life Sciences)
Jubilant Life Sciences
KCR
Kendle
Key Obs
King's College London
Lifetree Clinical Research
Lundbeck
MakroCare
Massachusetts General Hospital
Massachusetts Institute of Technology
MD Biosciences
MedAvante
Medivation
Merck KGaA
Merck & Co
Miicro
Ministry of Health, Labour and Welfare (MHLW)
Molecular Neuroimaging
MS Therapeutics
Myriad Genetics
National Institute of Aging (US)
National Institute of Mental Health (NIMH) [US]
National Institutes of Health (NIH) [US]
National Library of Medicine (US)
Neurodigitech
NEUROFIT
Neuroimage
NeuroSearch
Novartis
Noven Pharmaceuticals
Octapharma
Omega CRO
Omnicare Clinical Research
Ortho-McNeil Janssen Pharmaceutical
Otsuka
Paragon Biomedical
Parexel
Patient-Centered Outcomes Research Institute (PCORI)
Perceptive Informatics
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
PharmaNet
Pharmidex
PPD
PRA International
Premier Research
Prevalere Life Sciences
Pronexus Analytical
Prosensa Therapeutics
Psychmed (subsidiary of The Cognition Group)
PsychoGenics
QCTR
Quintiles
Ranbaxy Laboratories
Roche
sanofi-aventis
Schering-Plough
Shire
Stirling University (UK)
Takeda
Tangent Data
Targacept
Teva
The Cognition Group
Timaq Medical Imaging
Tufts Center for the Study of Drug Development
UCB
United BioSource Corp (UBC)
United Nations Educational, Scientific and Cultural Organization (UNESCO)
University of Michigan (US)
University of Prince Edward Island (Canada)
Veeda Clinical Research
Veeda Laboratories (former subsidiary of Veeda Clinical Research Group)
World Health Organization (WHO)
Wyeth (now part of Pfizer)
Skip to top


Ask Your Question

CNS Clinical Trials: World Market Prospects 2011-2026
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: